Announcements Trials
Browse Landscape

Phase

Phase NA 1Phase 1/2 1

Status

Completed 2Recruiting 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 57Breast 55Genitourinary 31Gynecologic 28Thoracic 25Dermatologic 22Other hematologic neoplasm 16Lymphoid 16Tumor-Agnostic 14Plasma cell 14Head & Neck 11Myeloid 9CNS 9Sarcoma 8Other solid neoplasm 6Endocrine 3Other neoplasm 2Other 2NET 2Classical hematology 2

Conditions

Neuroendocrine Tumors 1Midgut Neuroendocrine Tumors 1

Interventions

Everolimus 19lutetium Lu 177 dotatate 8Octreotide 8lanreotide 7pasireotide 6Temozolomide 6Sunitinib 6pembrolizumab 5gallium Ga 68 dotatate 5Positron Emission Tomography Computed Tomography 5surufatinib 4Sorafenib 4Data Collection 4Carboplatin 43-Iodobenzylguanidine 4Positron-Emission Tomography 3Nivolumab 3Magnetic Resonance Spectroscopy 3Etoposide 3Capecitabine 390Y-octreotide, DOTA-Tyr(3)- 3pentetreotide 2pazopanib 2lenvatinib 2fosbretabulin 2fluorodopa F 18 2cabozantinib 2avelumab 2arginyllysine 2Single Photon Emission Computed Tomography Computed Tomography 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Completed × Blood Specimen Collection × NET × Clear all
NCT03667092 2025-04-10

GENEBIOLuNET

University Hospital, Toulouse

Phase NA Completed
47 enrolled
EndocrineNET

Midgut Neuroendocrine Tumors

NCT02348749 2025-03-19

18F-MFBG Imaging for Evaluation of Neuroendocrine Malignancies

Memorial Sloan Kettering Cancer Center

Phase 1/2 Completed
48 enrolled
EndocrineNET

Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡